FDA 批的時候還沒有3期結果，現在結果出來了，

MODERNA'S BA.4/BA.5 TARGETING BIVALENT BOOSTER, MRNA-1273.222, MEETS PRIMARY ENDPOINT OF SUPERIORITY AGAINST OMICRON VARIANTS COMPARED TO BOOSTER DOSE OF MRNA-1273 IN PHASE 2/3 CLINICAL TRIAL